Methylphenidate

Generic Name: Methylphenidate

Brand Names: Adhansia, Aptensio, Biphentin, Concerta, Cotempla, Daytrana, Foquest, Jornay, Metadate, Methylin, Quillichew, Quillivant, Relexxii, Ritalin

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₉NO_₂

CAS Number: 113-45-1

Unique Ingredient Identifier: 207ZZ9QZ49

Background: Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve ...

Indication: Methylphenidate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years of age and older and for the treatment of narcolepsy.

Associated Conditions: Attention Deficit Hyperactivity Disorder (ADHD), Narcolepsy

Associated Therapies: -

Clinical Trials

Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints

Phase 4

Recruiting

Conditions: Posttraumatic Stress Disorder (PTSD)

Interventions: Drug: Methylphenidate
Drug: Placebo

First Posted Date: 2023-03-20

Last Posted Date: 2024-02-12

Lead Sponsor: VA Office of Research and Development

Target Recruit Count: 70

Registration Number: NCT05776056

Locations: 🇺🇸
Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama, United States
🇺🇸
VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington, United States

Oxygen Toxicity: Mechanisms in Humans

Not Applicable

Recruiting

Conditions: Seizures
Oxygen Toxicity
Hypercapnia

Interventions: Behavioral: Sleep Deprivation
Drug: Caffeine
Drug: Methylphenidate
Drug: Carbon Dioxide

First Posted Date: 2023-03-09

Last Posted Date: 2024-01-23

Lead Sponsor: Duke University

Target Recruit Count: 62

Registration Number: NCT05761756

Locations: 🇺🇸
Duke University Health Sustem, Durham, North Carolina, United States

Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy

Early Phase 1

Not yet recruiting

Conditions: Neurodevelopmental Disorders
Cerebral Palsy

Interventions: Drug: Modafinil
Other: Placebo
Drug: Methylphenidate

First Posted Date: 2023-01-09

Last Posted Date: 2023-03-08

Lead Sponsor: Kuwait University

Target Recruit Count: 30

Registration Number: NCT05675098

Locations: 🇰🇼
Physical Medicine and Rehabilitation Hospital, Kuwait, Kuwait

Neural Correlates of Acute Pain Dynamics

Phase 2

Completed

Conditions: Pain

Interventions: Drug: Placebo
Drug: Methylphenidate

First Posted Date: 2023-01-03

Last Posted Date: 2024-05-01

Lead Sponsor: Northwestern University

Target Recruit Count: 40

Registration Number: NCT05669924

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States

Methylphenidate for Apathy in Veterans With Parkinson's Disease

Phase 2

Not yet recruiting

Conditions: Apathy
Parkinson Disease

Interventions: Behavioral: Psychosocial intervention
Drug: Methylphenidate

First Posted Date: 2022-12-30

Last Posted Date: 2022-12-30

Lead Sponsor: Ralph H. Johnson VA Medical Center

Target Recruit Count: 60

Registration Number: NCT05669170

Biomarkers of ADHD Treatment Response

Phase 1

Completed

Conditions: ADHD

Interventions: Drug: Adderall-XR
Drug: Concerta

First Posted Date: 2022-12-14

Last Posted Date: 2024-12-18

Lead Sponsor: Boston Children's Hospital

Target Recruit Count: 16

Registration Number: NCT05650775

Locations: 🇺🇸
2 Brookline Place, Brookline, Massachusetts, United States

Orexin s Role in the Neurobiology of Substance Use Disorder

Not Applicable

Recruiting

Conditions: Nicotine Dependence

Interventions: Drug: Belsomra
Drug: Placebo
Drug: Methylphenidate

First Posted Date: 2022-11-30

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 140

Registration Number: NCT05630781

Locations: 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States

Towards an Understanding of the Mechanism of Action of Methylphenidate in ADHD

Not yet recruiting

Conditions: Attention Deficit Hyperactivity Disorder

Interventions: Drug: Methylphenidate

First Posted Date: 2022-11-01

Last Posted Date: 2023-05-15

Lead Sponsor: University of Dublin, Trinity College

Target Recruit Count: 35

Registration Number: NCT05600881

rTMS for Apathy Clinical Trial

Not Applicable

Recruiting

Conditions: Alzheimer Disease
Apathy in Dementia

Interventions: Device: rTMS
Drug: methylphenidate

First Posted Date: 2022-09-30

Last Posted Date: 2024-04-04

Lead Sponsor: Sunnybrook Health Sciences Centre

Target Recruit Count: 8

Registration Number: NCT05561205

Locations: 🇨🇦
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

Phase 2

Recruiting

Conditions: Sleep
Anxiety
Depression
Fatigue
Cancer

Interventions: Other: Placebo for Melatonin
Drug: Melatonin
Drug: Methylphenidate

First Posted Date: 2022-07-26

Last Posted Date: 2024-11-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 188

Registration Number: NCT05474846

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy